866-997-4948(US-Canada Toll Free)

Opaxio (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 27 Pages

 

GlobalDatas pharmaceuticals report, Opaxio (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020 provides Opaxio sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Opaxio including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Opaxio including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2015-2020 for Opaxio in the US

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8


3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11
3.3.6 12


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Opaxio 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Factors Affecting Sales of Opaxio 17
5.4.1 NSCLC Market 17
5.4.2 High Efficacy 17
5.4.3 Convenient Infusion 17
5.4.4 Caters to Niche Market 17
5.4.5 Increasing Popularity of Targeted Therapy 17
5.5 Drug Risk Benefit Score 18
5.5.1 Efficacy 18
5.5.2 Safety 18
5.5.3 Compliance 18
5.5.4 Dosing Convenience 18
5.6 Intensity of Competition 18
5.7 Sales forecast 19
5.7.1 Target Patient Pool of Opaxio 19
5.7.2 Dosing 20
5.7.3 Market Penetration 20
5.7.4 Annual Cost of Therapy 21
5.7.5 Sales Projections of Opaxio 21


6 NSCLC Market: Appendix 22
6.1 Market Definitions 22
6.2 List of Abberiviations 22
6.3 Research Methodology 22
6.3.1 Coverage 23
6.3.2 Secondary Research 23
6.3.3 Forecasting 23
6.3.4 Number of Patients Approved to take the Drug 24
6.3.5 Net Penetration of Drug 24
6.3.6 Net Annual Dosing 26
6.3.7 Annual Cost of Therapy 26
6.3.8 Primary Research 26
6.3.9 Expert Panels 26
6.4 Contact Us 27
6.5 Disclaimer 27
6.6 Sources 27

List of Table


Table 1: NSCLC, Incidences and Mortality, 2008-2030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Drug Risk Benefit Score 18
Table 4: Opaxio, NSCLC, The US, Sales Forecast ($m), 20152020 21

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: Percentage Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: NSCLC, Global, Incidence (in millions), 2008-2030 10
Figure 8: Oncology, Global, Incidence (in millions), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Drug Model Diagram of Opaxio 20
Figure 13: Opaxio, NSCLC, The US, Sales Forecast ($m), 20152020 21
Figure 14: GlobalData Methodology 22
Figure 15: Drug Model Diagram 24
Figure 16: Patients Approved for the Drug 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *